CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy

Bulletin Express

Jun 25

CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).

The product is already approved in China for children aged 3 months to 6 years (up to 83 months), where clinical trials demonstrated favorable safety and immunogenicity against Group ACYW135 Neisseria meningitidis. A clinical summary for an age-expansion study covering individuals aged 7 to 59 years has been completed, and a supplemental application is in preparation.

Management regards the Argentine approval as an important milestone in the vaccine’s international rollout, enhancing brand recognition and supporting the company’s broader overseas roadmap focused on Southeast Asia, the Middle East and Latin America. Future sales volumes and timing in Argentina will depend on market demand within the approved population.

The board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1176634791"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176634791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176634791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176634791","market":"hk","top_or_hot":-1,"title":"CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).</p>\n<p>The product is already approved in China for children aged 3 months to 6 years (up to 83 months), where clinical trials demonstrated favorable safety and immunogenicity against Group ACYW135 Neisseria meningitidis. A clinical summary for an age-expansion study covering individuals aged 7 to 59 years has been completed, and a supplemental application is in preparation.</p>\n<p>Management regards the Argentine approval as an important milestone in the vaccine’s international rollout, enhancing brand recognition and supporting the company’s broader overseas roadmap focused on Southeast Asia, the Middle East and Latin America. Future sales volumes and timing in Argentina will depend on market demand within the approved population.</p>\n<p>The board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-25 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).</p>\n<p>The product is already approved in China for children aged 3 months to 6 years (up to 83 months), where clinical trials demonstrated favorable safety and immunogenicity against Group ACYW135 Neisseria meningitidis. A clinical summary for an age-expansion study covering individuals aged 7 to 59 years has been completed, and a supplemental application is in preparation.</p>\n<p>Management regards the Argentine approval as an important milestone in the vaccine’s international rollout, enhancing brand recognition and supporting the company’s broader overseas roadmap focused on Southeast Asia, the Middle East and Latin America. Future sales volumes and timing in Argentina will depend on market demand within the approved population.</p>\n<p>The board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1176634791","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176634791","pubTimestamp":1782379439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物：MCV4疫苗获得阿根廷注册，推进全球战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. announced that its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), marketed as Menhycia®, has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).\nThe product is already approved in China for children aged 3 months to 6 years (up to 83 months), where clinical trials demonstrated favorable safety and immunogenicity against Group ACYW135 Neisseria meningitidis. A clinical summary for an age-expansion study covering individuals aged 7 to 59 years has been completed, and a supplemental application is in preparation.\nManagement regards the Argentine approval as an important milestone in the vaccine’s international rollout, enhancing brand recognition and supporting the company’s broader overseas roadmap focused on Southeast Asia, the Middle East and Latin America. Future sales volumes and timing in Argentina will depend on market demand within the approved population.\nThe board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}